Increased midkine expression correlates with desmoid tumour recurrence: A potential biomarker and therapeutic target

Journal of Pathology

Volumn 225, Issue 4, 2011, Pages 574-582

  Colombo, Chiara ^a   Creighton, Chad J ^b   Ghadimi, Markus P ^a   Bolshakov, Svetlana ^a   Warneke, Carla L ^a   Zhang, Yiqun ^b   Lusby, Kristelle ^a   Zhu, Shirley ^c   Lazar, Alexander J ^a,d   West, Robert B ^c   De Rijn, Matt Van ^c   Lev, Dina ^a,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

catenin; ADAM12; desmoid tumours; gene arrays; LEF TCF; midkine; MMP2; tissue microarrays

Indexed keywords

ADAM PROTEIN; ADAM12 PROTEIN; BETA CATENIN; BIOLOGICAL MARKER; GELATINASE A; LYMPHOID ENHANCER FACTOR 1; MIDKINE; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BIOINFORMATICS; CELL ADHESION; CELL CULTURE; CELL INVASION; CELL MIGRATION; DESMOID TUMOR; DOWN REGULATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN MOTIF; SOLITARY FIBROUS TUMOR; TISSUE MICROARRAY; TUMOR RECURRENCE; UPREGULATION; WOUND HEALING;

CYTOKINES; DOWN-REGULATION; FIBROMATOSIS, AGGRESSIVE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SOFT TISSUE NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 81355149685     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2951     Document Type: Article

References (63)

1. Kotiligam D, Lazar AJ, Pollock RE, et al., Desmoid tumor: a disease opportune for molecular insights. Histol Histopathol 2008; 23: 117-126.
2. Mendenhall WM, Zlotecki RA, Morris CG, et al., Aggressive fibromatosis. Am J Clin Oncol 2005; 28: 211-215.
3. Lips DJ, Barker N, Clevers H, et al., The role of APC and β-catenin in the aetiology of aggressive fibromatosis (desmoid tumors). Eur J Surg Oncol 2009; 35: 3-10.
4. Lazar AJ, Tuvin D, Hajibashi S, et al., Specific mutations in the β-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 2008; 173: 1518-1527.
5. Bhattacharya B, Dilworth HP, Iacobuzio-Donahue C, et al., Nuclear β-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am J Surg Pathol 2005; 29: 653-659.
6. Carlson JW, Fletcher CD,. Immunohistochemistry for β-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology 2007; 51: 509-514.
7. Montgomery E, Folpe AL,. The diagnostic value of β-catenin immunohistochemistry. Adv Anat Pathol 2005; 12: 350-356.
8. Lazar AJ, Hajibashi S, Lev D,. Desmoid tumor: from surgical extirpation to molecular dissection. Curr Opin Oncol 2009; 21: 352-359.
9. Merchant NB, Lewis JJ, Woodruff JM, et al., Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer 1999; 86: 2045-2052.
10. Gronchi A, Casali PG, Mariani L, et al., Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol 2003; 21: 1390-1397.
11. Lev D, Kotilingam D, Wei C, et al., Optimizing treatment of desmoid tumors. J Clin Oncol 2007; 25: 1785-1791.
12. Jenkins NH, Freedman LS, McKibbin B,. Spontaneous regression of a desmoid tumour. J Bone Joint Surg Br 1986; 68: 780-781.
13. Dalen BP, Geijer M, Kvist H, et al., Clinical and imaging observations of desmoid tumors left without treatment. Acta Orthop 2006; 77: 932-937.
14. Bonvalot S, Eldweny H, Haddad V, et al., Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 2008; 34: 462-468.
15. Fiore M, Rimareix F, Mariani L, et al., Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 2009; 16: 2587-2593.
16. de Bree E, Keus R, Melissas J, et al., Desmoid tumors: need for an individualized approach. Expert Rev Anticancer Ther 2009; 9: 525-535.
17. Gounder MM, Lefkowitz RA, Hameed M, et al., Activity of sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 2011; 17: 4082-4090.
18. Potti A, Dressman HK, Bild A, et al., Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006; 12: 1294-1300.
19. van de Vijver MJ, He YD, van't Veer LJ, et al., A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
20. DeRisi J, Penland L, Brown PO, et al., Use of a cDNA microarray to analyze gene expression patterns in human cancer. Nat Genet 1996; 14: 457-460.
21. Golub TR, Slonim DK, Tamayo P, et al., Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-537.
22. Alizadeh AA, Eisen MB, Davis RE, et al., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
23. Lapointe J, Li C, Higgins JP, et al., Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101: 811-816.
24. Bittner M, Meltzer P, Chen Y, et al., Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000; 406: 536-540.
25. Nielsen TO, West RB, Linn SC, et al., Molecular characterization of soft tissue tumours: a gene expression study. Lancet 2002; 359: 1301-1307.
26. Lee YF, John M, Edwards S, et al., Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling. Br J Cancer 2003; 88: 510-515.
27. Baird K, Davis S, Antonescu CR, et al., Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 2005; 65: 9226-9235.
28. Francis P, Namlos HM, Muller C, et al., Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genom 2007; 8: 73.
29. Nakayama R, Nemoto T, Takahashi H, et al., Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol 2007; 20: 749-759.
30. Staudt LM,. Molecular diagnosis of the hematologic cancer. N Engl J Med 2003; 348: 1777-1785.
31. Bao T, Davidson NE,. Gene expression profiling of breast cancer. Adv Surg 2008; 42: 249-260.
32. Bacac M, Migliavacca E, Stehle JC, et al., A gene expression signature that distinguishes desmoid tumours from nodular fasciitis. J Pathol 2006; 208: 543-553.
33. Beck AH, Weng Z, Witten DM, et al., 3′-end sequencing for expression quantification (3SEQ) from archival tumor samples. PLoS One 2010; 5 (1): e8768.
34. Denys H, Jadidizadeh A, Amini Nik S, et al., Identification of IGFBP-6 as a significantly downregulated gene by β-catenin in desmoid tumors. Oncogene 2004; 23: 654-664.
35. Skubitz KM, Skubitz AP,. Gene expression in aggressive fibromatosis. J Lab Clin Med 2004; 143: 89-98.
36. Skubitz KM, Pambuccian S, Manivel JC, et al., Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. J Transl Med 2008; 6: 23.
37. West RB, Nuyten DS, Subramanian S, et al., Determination of stromal signatures in breast carcinoma. PLoS Biol 2005; 3: e187.
38. Jin Z, Lahat G, Korchin B, et al., Midkine enhances soft-tissue sarcoma growth: a possible novel therapeutic target. Clin Cancer Res 2008; 14: 5033-5042.
39. Lahat G, Zhu QS, Huang KL, et al., Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One 2010; 5: e10105.
40. Lopez G, Liu J, Ren W, et al., Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res 2009; 15 (10): 3472-3483.
41. Saldanha AJ,. Java Treeview-extensible visualization of microarray data. Bioinformatics 2004; 20 (17): 3246-3248.
42. Creighton CJ, Nagaraja AK, Hanash SM, et al., A bioinformatics tool for linking gene expression profiling results with public databases of microRNA target predictions. RNA 14: 2290-2296.
43. Subramanian A, Tamayo P, Mootha VK, et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
44. Storey JD, Tibshirani R,. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100 (16): 9440-9445.
45. Tetsu O, McCormick F,. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-426.
46. Jho EH, Zhang T, Domon C, et al., Wnt/β-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 2002; 22: 1172-1183.
47. Batlle E, Henderson JT, Beghtel H, et al., β-Catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 2002; 111: 251-263.
48. van der Heyden MA, Rook MB, Hermans MM, et al., Identification of connexin43 as a functional target for Wnt signalling. J Cell Sci 1998; 111 (pt 12): 1741-1749.
49. Rahmani M, Read JT, Carthy JM, et al., Regulation of the versican promoter by the β-catenin-T-cell factor complex in vascular smooth muscle cells. J Biol Chem 2005; 280: 13019-13028.
50. He TC, Sparks AB, Rago C, et al., Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-1512.
51. Crawford HC, Fingleton BM, Rudolph-Owen LA, et al., The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors. Oncogene 1999; 18: 2883-2891.
52. Poon R, Smits R, Li C, et al., Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor). Oncogene 2001; 20: 451-460.
53. Amini Nik S, Hohenstein P, Jadidizadeh A, et al., Upregulation of Wilms' tumor gene 1 (WT1) in desmoid tumors. Int J Cancer 2005; 114: 202-208.
54. Lepourcelet M, Chen YN, France DS, et al., Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer Cell 2004; 5: 91-102.
55. Muramatsu T,. Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases. Proc Jpn Acad Ser B Phys Biol Sci 2010; 86: 410-425.
56. Shimada H, Nabeya Y, Tagawa M, et al., Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci 2003; 94: 628-632.
57. Ikematsu S, Nakagawara A, Nakamura Y, et al., Plasma midkine level is a prognostic factor for human neuroblastoma. Cancer Sci 2008; 99: 2070-2074.
58. Tanabe K, Matsumoto M, Ikematsu S, et al., Midkine and its clinical significance in endometrial carcinoma. Cancer Sci 2008; 99: 1125-1130.
59. Choudhuri R, Zhang HT, Donnini S, et al., An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 1997; 57: 1814-1819.
60. Kadomatsu K, Hagihara M, Akhter S, et al., Midkine induces the transformation of NIH3T3 cells. Br J Cancer 1997; 75: 354-359.
61. Qi M, Ikematsu S, Maeda N, et al., Haptotactic migration induced by midkine. Involvement of protein-tyrosine phosphatase. Mitogen-activated protein kinase, and phosphatidylinositol 3-kinase. J Biol Chem 2001; 276: 15868-15875.
62. Mashour GA, Ratner N, Khan GA, et al., The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene 2001; 20: 97-105.
63. Yamamoto H, Muramatsu H, Nakanishi T, et al., Midkine as a molecular target: comparison of effects of chondroitin sulfate E and siRNA. Biochem Biophys Res Commun 2006; 351: 915-919.